|
1
|
Liu F, Wang XD and Du SY: Production of
gold/silver doped carbon nanocomposites for effective photothermal
therapy of colon cancer. Sci Rep. 10(7618)2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wang X, Zhong X, Lei H, Geng Y, Zhao Q,
Gong F, Yang Z, Dong Z, Liu Z and Cheng L: Hollow Cu2Se nanozymes
for tumor photothermal-catalytic therapy. Chem Mater. 31:6174–6186.
2019.
|
|
3
|
Roper J, Tammela T, Cetinbas NM, Akkad A,
Roghanian A, Rickelt S, Almeqdadi M, Wu K, Oberli MA,
Sanchez-Rivera FJ, et al: In vivo genome editing and organoid
transplantation models of colorectal cancer and metastasis. Nat
Biotechnol. 35:569–576. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
4
|
Vasaikar S, Huang C, Wang X, Petyuk VA,
Savage SR, Wen B, Dou Y, Zhang Y, Shi Z, Arshad OA, et al: Clinical
proteomic tumor analysis, proteogenomic analysis of human colon
cancer reveals new therapeutic opportunities. Cell. 177:1035–1049.
2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Araghi M, Soerjomataram I, Jenkins M,
Brierley J, Morris E, Bray F and Arnold M: Global trends in
colorectal cancer mortality: Projections to the year 2035. Int J
Cancer. 144:2992–3000. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Feletto E, Yu XQ, Lew JB, St John DJB,
Jenkins MA, Macrae FA, Mahady SE and Canfell K: Trends in colon and
rectal cancer incidence in australia from 1982 to 2014: Analysis of
data on over 375,000 cases. Cancer Epidemiol Biomarkers Prev.
28:83–90. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
MacKay JA, Chen M, McDaniel JR, Liu W,
Simnick AJ and Chilkoti A: Self-assembling chimeric
polypeptide-doxorubicin conjugate nanoparticles that abolish
tumours after a single injection. Nat Mater. 8:993–999.
2009.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Xu L, Gordon R, Farmer R, Pattanayak A,
Binkowski A, Huang X, Avram M, Krishna S, Voll E, Pavese J, et al:
Precision therapeutic targeting of human cancer cell motility. Nat
Commun. 9(2454)2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Keklikoglou I, Cianciaruso C, Guc E,
Squadrito ML, Spring LM, Tazzyman S, Lambein L, Poissonnier A,
Ferraro GB, Baer C, et al: Chemotherapy elicits pro-metastatic
extracellular vesicles in breast cancer models. Nat Cell Biol.
21:190–202. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Park NH, Cheng W, Lai F, Yang C, Florez de
Sessions P, Periaswamy B, Wenhan Chu C, Bianco S, Liu S,
Venkataraman S, et al: Addressing drug resistance in cancer with
macromolecular chemotherapeutic agents. J Am Chem Soc.
140:4244–4252. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Baskar R, Lee KA, Yeo R and Yeoh KW:
Cancer and radiation therapy: Current advances and future
directions. Int J Med Sci. 9:193–199. 2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Huang Z, Wang Y, Yao D, Wu J, Hu Y and
Yuan A: Nanoscale coordination polymers induce immunogenic cell
death by amplifying radiation therapy mediated oxidative stress.
Nat Commun. 12(145)2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Moding EJ, Kastan MB and Kirsch DG:
Strategies for optimizing the response of cancer and normal tissues
to radiation. Nat Rev Drug Discov. 12:526–542. 2013.PubMed/NCBI View
Article : Google Scholar
|
|
14
|
Song G, Cheng L, Chao Y, Yang K and Liu Z:
Emerging nanotechnology and advanced materials for cancer radiation
therapy. Adv Mater: Jun 23, 2017 (Epub ahead of print).
|
|
15
|
Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu
YL, Liu LF and Yeh ET: Identification of the molecular basis of
doxorubicin-induced cardiotoxicity. Nat Med. 18:1639–1642.
2012.PubMed/NCBI View
Article : Google Scholar
|
|
16
|
Zhu AX, Rosmorduc O, Evans TR, Ross PJ,
Santoro A, Carrilho FJ, Bruix J, Qin S, Thuluvath PJ, Llovet JM, et
al: SEARCH: A phase III, randomized, double-blind,
placebo-controlled trial of sorafenib plus erlotinib in patients
with advanced hepatocellular carcinoma. J Clin Oncol. 33:559–566.
2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Breglio AM, Rusheen AE, Shide ED,
Fernandez KA, Spielbauer KK, McLachlin KM, Hall MD, Amable L and
Cunningham LL: Cisplatin is retained in the cochlea indefinitely
following chemotherapy. Nat Commun. 8(1654)2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Sara JD, Kaur J, Khodadadi R, Rehman M,
Lobo R, Chakrabarti S, Herrmann J, Lerman A and Grothey A:
5-fluorouracil and cardiotoxicity: A review. Ther Adv Med Oncol.
10(1758835918780140)2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Banik K, Ranaware AM, Harsha C, Nitesh T,
Girisa S, Deshpande V, Fan L, Nalawade SP, Sethi G and Kunnumakkara
AB: Piceatannol: A natural stilbene for the prevention and
treatment of cancer. Pharmacol Res. 153(104635)2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ko HS, Lee HJ, Kim SH and Lee EO:
Piceatannol suppresses breast cancer cell invasion through the
inhibition of MMP-9: Involvement of PI3K/AKT and NF-κB pathways. J
Agric Food Chem. 60:4083–4089. 2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Lee YM, Lim DY, Cho HJ, Seon MR, Kim JK,
Lee BY and Park JH: Piceatannol, a natural stilbene from grapes,
induces G1 cell cycle arrest in androgen-insensitive DU145 human
prostate cancer cells via the inhibition of CDK activity. Cancer
Lett. 285:166–173. 2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Xu Q, Fu Q, Li Z, Liu H, Wang Y, Lin X, He
R, Zhang X, Ju Z, Campisi J, et al: The flavonoid procyanidin C1
has senotherapeutic activity and increases lifespan in mice. Nat
Metab. 3:1706–1726. 2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zhang L, Wang S, Liu Z, Zhang L, Wang S
and Wang B: Procyanidin, a kind of biological flavonoid, induces
protective anti-tumor immunity and protects mice from lethal B16F10
challenge. Int Immunopharmacol. 47:251–258. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Shang XJ, Yao G, Ge JP, Sun Y, Teng WH and
Huang YF: Procyanidin induces apoptosis and necrosis of prostate
cancer cell line PC-3 in a mitochondrion-dependent manner. J
Androl. 30:122–126. 2009.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Lei Y, Ren X, Chen J, Liu D and Ruan J:
Protective effects of grape seed-derived procyanidin extract
against carrageenan-induced abacterial prostatitis in rats. J Funct
Foods. 7:416–424. 2014.
|
|
26
|
Li S, Kodama EN, Inoue Y, Tani H, Matsuura
Y, Zhang J, Tanaka T and Hattori T: Procyanidin B1 purified from
Cinnamomi cortex suppresses hepatitis C virus replication. Antivir
Chem Chemother. 20:239–248. 2010.PubMed/NCBI View
Article : Google Scholar
|
|
27
|
Na W, Ma B, Shi S, Chen Y, Zhang H, Zhan Y
and An H: Procyanidin B1, a novel and specific inhibitor of Kv10.1
channel, suppresses the evolution of hepatoma. Biochem Pharmacol.
178(114089)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Koteswari LL, Kumari S, Kumar AB and Malla
RR: A comparative anticancer study on procyanidin C1 against
receptor positive and receptor negative breast cancer. Nat Prod
Res. 34:3267–3274. 2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Lee Y: Cancer chemopreventive potential of
procyanidin. Toxicol Res. 33:273–282. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Okamoto S, Ishihara S, Okamoto T, Doi S,
Harui K, Higashino Y, Kawasaki T, Nakajima N and Saito A:
Inhibitory activity of synthesized acetylated Procyanidin B1
analogs against HeLa S3 cells proliferation. Molecules.
19:1775–1785. 2014.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Mao JT, Xue B, Smoake J, Lu QY, Park H,
Henning SM, Burns W, Bernabei A, Elashoff D, Serio KJ and Massie L:
MicroRNA-19a/b mediates grape seed procyanidin extract-induced
anti-neoplastic effects against lung cancer. J Nutr Biochem.
34:118–125. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Cagel M, Grotz E, Bernabeu E, Moretton MA
and Chiappetta DA: Doxorubicin: Nanotechnological overviews from
bench to bedside. Drug Discov Today. 22:270–281. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Tacar O, Sriamornsak P and Dass CR:
Doxorubicin: An update on anticancer molecular action, toxicity and
novel drug delivery systems. J Pharm Pharmacol. 65:157–170.
2013.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Ghosh P, Tiwari H, Lakkakula J, Roy A,
Emran TB, Rashid S, Alghamdi S, Rajab BS, Almehmadi M, Allahyani M,
et al: A decade's worth of impact: Dox loaded liposomes in
anticancer activity. Mater Today Adv. 16(100313)2022.
|
|
36
|
van Pelt-Sprangers MJ, Geijteman EC, Alsma
J, Boere IA, Mathijssen RH and Schuit SC: Oromandibular dystonia: A
serious side effect of capecitabine. BMC Cancer.
15(115)2015.PubMed/NCBI View Article : Google Scholar
|
|
37
|
James E, Podoltsev N, Salehi E, Curtis BR
and Saif MW: Oxaliplatin-induced immune thrombocytopenia: Another
cumulative dose-dependent side effect? Clin Colorectal Cancer.
8:220–224. 2009.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Zhao J, Zhang X, Cui X, Wang D, Zhang B
and Ban L: Loss of fingerprints as a side effect of capecitabine
therapy: Case report and literature review. Oncol Res. 28:103–106.
2020.PubMed/NCBI View Article : Google Scholar
|
